In summary, while several antidiabetic drug classes possess neuroprotective potential, current evidence most strongly supports SGLT2 inhibitors and GLP-1RAs as leading candidates for repurposing in neurodegenerative and cerebrovascular disease. This evidence concerns the gene SLC5A2 and cerebrovascular disorder.